[EN] PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS [FR] PYRAZOLOPYRIDINE ET DÉRIVÉS DE PYRAZOLOPYRIMIDINE EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA MÉLANOCORTINE-4
[EN] PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS [FR] PYRAZOLOPYRIDINE ET DÉRIVÉS DE PYRAZOLOPYRIMIDINE EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA MÉLANOCORTINE-4
PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
申请人:Bouvier Michel
公开号:US20140057894A1
公开(公告)日:2014-02-27
Disclosed herein is a compound of Formula I: wherein X, R
1
, R
2
, and R
3
are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
申请人:Bouvier Michel
公开号:US09018395B2
公开(公告)日:2015-04-28
Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
[EN] PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS<br/>[FR] PYRAZOLOPYRIDINE ET DÉRIVÉS DE PYRAZOLOPYRIMIDINE EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA MÉLANOCORTINE-4
申请人:UNIV MONTREAL
公开号:WO2012100342A1
公开(公告)日:2012-08-02
Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.